Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study

ConclusionsThis study suggests that there is no particular concern about adverse drug reactions or the efficacy of topiroxostat for hyperuricemic patients with or without gout in a post-marketing setting in Japan.

http://link.springer.com/10.1007/s40261-020-00941-3

Source: Clinical Drug Investigation - July 2, 2020 Category: Drugs & Pharmacology Source Type: research